knowledge -WSS

knowledge

author：leisure time 2025-09-30 22:22:24 - browse：12957

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Asbestos ban is immediate, but health effects will linger for decades

knowledge

hotspot

explore

WSS

Asbestos ban is immediate, but health effects will linger for decades

Medicare Advantage insurers pressure Biden for bigger payments

Medical devices makers are asking for forgiveness, not permission

'Patient friction coefficient' can gauge a clinical trial's patient burden

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

What Kate Middleton's cancer revelation might teach the world

hotspot

knowledge

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

With Wegovy coverage, Medicare patients may face high costs

Wildfire smoke exposes gaps in outdoor worker protections

International team creates first chimeric human

Virginia high school admissions case could be legal follow

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Medical records are filled with copy

Pregnancy ages women, but effects reverse after delivery

George Santos makes 1st court appearance after pleading not guilty to 13 counts

ALS groups 'won't be played again' by the FDA, drug sponsors

focus

U.K. officials, researchers try to ease path for bespoke genetic treatments

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Erich Jarvis studies song birds to learn about human stuttering

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

An inside look at PIPEs, biotech's buzzy new financing tool

ALS groups 'won't be played again' by the FDA, drug sponsors

knowledge

hotspot

explore

focus